Androcur more supervised prescriptions-Marie-Claire
Prescription and monitoring during the treatment of this drug which increases the risk of developing meningiomas (brain tumors) will now be more supervised.
By
For several months in the crosshairs of patients but also drug safety bodies, Androcur, a progesterone derivative marketed by Bayer and generally prescribed in cases of hirsutime (extreme hair), but also-horses of marketing-as anti-acneic or for gynecological pathologies such as polycystic ovary syndrome or endometriosis , will now be much more framed in Its prescription but also in its surveillance during treatment.
Joint recommendations for professionals and patients
If, in 80% of cases, these tumors prove benign, they can nevertheless leave significant neurological sequelae affecting the comfort of life. In fact, the drug and its generics are now associated with a list of new recommendations* unveiled on June 12, 2019 by the National Agency for the Safety of Medicines and Health Products (ANSM).
Find the other Amavea articles here
